Categories
Change Password!
Reset Password!
Silybum marianum and alpha-lipoic acid when combined with a Mediterranean diet reduce hepatic steatosis, improve biochemical parameters, and lower visceral fat while being safe and well-tolerated.
In accordance with the findings of a randomized clinical trial, the combination of Silybum marianum (SM) and alpha-lipoic acid (ALA), when paired with the Mediterranean diet (MD), may help reduce visceral fat and liver steatosis in metabolic dysfunction-associated steatotic liver disease (MASLD).
Researchers enrolled 50 Mexican patients (mean age: 54 years, 74% female) diagnosed with MASLD. The enrolled subjects were randomly allocated to 2 groups:
The study lasted 24 weeks, with assessments at baseline, week 12, and week 24. Researchers evaluated anthropometric parameters (visceral fat, umbilical circumference), metabolic parameters, and liver function (measured using transient elastography and the controlled attenuation parameter [CAP]).
Both groups showed reductions in visceral fat and umbilical circumference, but the improvement was markedly more pronounced in Group A (P = 0.045 and 0.003, respectively). Liver fat accumulation, measured by the CAP, gradually declined and remained stable at 12 and 24 weeks in Group A (P = 0.026). In contrast, Group B experienced a more noticeable reduction at week 12, but no further change by week 24 (∆CAP: -27 dB/m).
Mild adverse effects were witnessed in 16% of participants in both groups (P = 0.641), with no vital differences between treatments. This study suggests that SM-ALA combined with MD can improve metabolic parameters, leading to reductions in visceral fat and hepatic steatosis in MASLD-affected patients.
World Journal of Hepatology
Effect of alpha-lipoic acid and Silybum marianum supplementation with a Mediterranean diet on metabolic dysfunction-associated steatosis
Ana D Cano Contreras et al.
Comments (0)